Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Imatinib mesylate in thymic epithelial malignancies.

Palmieri G, Marino M, Buonerba C, Federico P, Conti S, Milella M, Petillo L, Evoli A, Lalle M, Ceribelli A, Merola G, Matano E, Sioletic S, De Placido S, Di Lorenzo G, Damiano V.

Cancer Chemother Pharmacol. 2012 Feb;69(2):309-15. doi: 10.1007/s00280-011-1690-0. Epub 2011 Jun 28.

PMID:
21710245
2.

Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.

Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL.

J Clin Oncol. 2005 Jan 20;23(3):585-90.

PMID:
15659505
3.

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.

Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA.

Cancer. 2006 May 1;106(9):2005-11.

4.

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC.

J Clin Oncol. 2008 Jul 10;26(20):3418-25. doi: 10.1200/JCO.2007.14.3420.

PMID:
18612157
5.

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Levenback CF, Gershenson DM.

Gynecol Oncol. 2006 Apr;101(1):126-31. Epub 2005 Nov 3.

PMID:
16271384
6.

Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.

Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC.

J Thorac Oncol. 2009 Oct;4(10):1270-3. doi: 10.1097/JTO.0b013e3181b6be57.

7.

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA.

J Clin Oncol. 2008 Nov 20;26(33):5360-7. doi: 10.1200/JCO.2008.17.4284. Epub 2008 Oct 27.

8.

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS.

Eur J Cancer. 2003 Sep;39(14):2006-11.

PMID:
12957454
9.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC.

J Clin Oncol. 2008 Feb 1;26(4):626-32. doi: 10.1200/JCO.2007.13.4452.

PMID:
18235122
10.

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.

Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, Breen T, McClean J, Stephens D, Whalen C, Sutton G.

Cancer. 2008 Aug 15;113(4):723-32. doi: 10.1002/cncr.23605.

11.

Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.

Buti S, Donini M, Sergio P, Garagnani L, Schirosi L, Passalacqua R, Rossi G.

J Clin Oncol. 2011 Nov 20;29(33):e803-5. doi: 10.1200/JCO.2011.36.6427. Epub 2011 Oct 3. No abstract available.

PMID:
21969494
12.

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA.

Breast Cancer Res Treat. 2005 Mar;90(2):157-63.

PMID:
15803362
13.

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

Demetri GD.

Semin Oncol. 2001 Oct;28(5 Suppl 17):19-26. Review.

PMID:
11740803
14.

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).

Le Cesne A, Blay JY, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O.

Eur J Cancer. 2010 May;46(8):1344-51. doi: 10.1016/j.ejca.2010.02.014. Epub 2010 Mar 6.

PMID:
20211560
15.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H.

J Clin Oncol. 2008 Feb 1;26(4):620-5. doi: 10.1200/JCO.2007.13.4403.

PMID:
18235121
16.

Phase II study of imatinib in patients with small cell lung cancer.

Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, Le Chevalier T.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5880-7.

17.

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.

Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG; Imatinib Target Exploration Consortium Study B2225.

Clin Cancer Res. 2008 May 1;14(9):2717-25. doi: 10.1158/1078-0432.CCR-07-4575.

18.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H.

N Engl J Med. 2002 Aug 15;347(7):472-80.

19.

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.

Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M, Heelan RT.

Cancer. 2005 May 15;103(10):2128-31.

20.

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.

Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.

Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23.

PMID:
19307738

Supplemental Content

Support Center